TY - JOUR AU - Molnár, István Artúr AU - Molnár, Béla Ákos AU - Vízkeleti, Laura AU - Fekete, Krisztina AU - Tamás, Judit AU - Deak, P AU - Szundi, Csilla AU - Székely, Borbála AU - Moldvay, Judit AU - Vari-Kakas, S AU - Szász, Attila Marcell AU - Ács, Balázs AU - Kulka, Janina AU - Tőkés, Anna-Mária TI - Breast carcinoma subtypes show different patterns of metastatic behavior JF - VIRCHOWS ARCHIV J2 - VIRCHOWS ARCH VL - 470 PY - 2017 IS - 3 SP - 275 EP - 283 PG - 9 SN - 0945-6317 DO - 10.1007/s00428-017-2065-7 UR - https://m2.mtmt.hu/api/publication/3177516 ID - 3177516 N1 - István Artúr Molnár and Béla Ákos Molnár equally contributed. AB - The aim of our retrospective study was to analyze patterns of subtype specific metastatic spread and to identify the time course of distant metastases. A consecutive series of 490 patients with breast cancer who underwent surgery and postoperative treatment at Semmelweis University, Hungary, and diagnosed between the years 2000 and 2007 was identified from the archives of the 2nd Department of Pathology, Hungary. Molecular subtypes were defined based on the 2011 St. Gallen recommendations. Statistical analysis was performed with SPSS Statistics for Windows, Version 22.0. Distant metastasis free survival (DMFS) was defined as the time elapsed between the first pathological diagnosis of the tumor and the first distant metastasis detection. Distant metastases were detected in 124 patients. Mean time to develop metastasis was 29 months (range 0-127 months). The longest DMFS was observed in the Luminal A (LUMA) subtype (mean 39 months) whereas the shortest was seen in the HER2-positive (HER2+) subtype (mean 21 months; p = 0.012). We confirmed that HER2+ tumors carry a higher risk for distant metastases (42.1%). LUMA-associated metastases were found to be solitary in 59% of cases, whereas HER2+ tumors showed multiple metastases in 79.2% of cases. LUMA tumors showed a preference for bone-only metastasis as compared with HER2+ and triple negative breast cancer (TNBC) cases, which exhibited a higher rate of brain metastasis. The most frequent second metastatic sites of hormone receptor (HR) positive tumors were the lung and liver, whereas the brain was the most affected organ in HR-negative (HR-) cases. Tumor subtypes differ in DMFS and in pattern of distant metastases. HER2+ tumors featured the most aggressive clinical course. Further identification of subtype-specific factors influencing prognosis might have an impact on clinical care and decision-making. LA - English DB - MTMT ER - TY - JOUR AU - Li, Yang AU - Zou, Lihua AU - Li, Qiyuan AU - Haibe-Kains, Benjamin AU - Tian, Ruiyang AU - Li, Yan AU - Desmedt, Christine AU - Sotiriou, Christos AU - Szállási, Zoltán AU - Iglehart, J Dirk AU - Richardson, Andrea L AU - Wang, Zhigang Charles TI - Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer JF - NATURE MEDICINE J2 - NAT MED VL - 16 PY - 2010 IS - 2 SP - 214 EP - 218 PG - 5 SN - 1078-8956 DO - 10.1038/nm.2090 UR - https://m2.mtmt.hu/api/publication/23080938 ID - 23080938 N1 - Funding Agency and Grant Number: NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393, P50CA089393] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50 CA089393, CA89393, P50 CA089393-10, P50 CA089393-01, BC053041] Funding Source: Medline Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States Department of Biostatistics, Harvard School of Public Health, Boston, MA, United States Center for Biological Sequence Analysis, Technical University of Denmark, Lyngby, Denmark Medical Oncology Department, Jules Bordet Institute, Brussels, Belgium Machine Learning Group, Université Libre de Bruxelles, Brussels, Belgium Children's Hospital Informatics Program, Harvard-Massachusetts Institute of Technology, Harvard Medical School, Boston, MA, United States Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States Cited By :220 Export Date: 19 November 2020 CODEN: NAMEF Correspondence Address: Richardson, A. L.; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, United States; email: arichardson@partners.org LA - English DB - MTMT ER -